Mustang Bio Capital Expenditures (CapEx) Growth & History (MBIO)
Mustang Bio's capital expenditures (capex) was $0 for fiscal 2024.
View full Mustang Bio company overviewMustang Bio annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $0 | −$64,000 | — |
| 2023 | 2023-12-31 | $64,000 | −$2.6M | −97.64% |
| 2022 | 2022-12-31 | $2.7M | −$1.3M | −31.91% |
| 2021 | 2021-12-31 | $4.0M | $2.1M | +107.06% |
| 2020 | 2020-12-31 | $1.9M | −$420,000 | −17.91% |
| 2019 | 2019-12-31 | $2.3M | −$4.5M | −65.87% |
| 2018 | 2018-12-31 | $6.9M | $6.4M | +1520.28% |
| 2017 | 2017-12-31 | $424,000 | $424,000 | — |
| 2016 | 2016-12-31 | $0 | — | — |
Mustang Bio quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q4 2023 | 2023-12-31 | $30,000 | −$65,000 | −68.42% |
| Q3 2023 | 2023-09-30 | $0 | −$979,000 | — |
| Q2 2023 | 2023-06-30 | $34,000 | −$272,000 | −88.89% |
| Q1 2023 | 2023-03-31 | $0 | −$1.3M | — |
| Q4 2022 | 2022-12-31 | $95,000 | −$1.3M | −93.10% |
| Q3 2022 | 2022-09-30 | $979,000 | $519,000 | +112.83% |
| Q2 2022 | 2022-06-30 | $306,000 | −$1.4M | −81.90% |
| Q1 2022 | 2022-03-31 | $1.3M | $876,000 | +191.27% |
| Q4 2021 | 2021-12-31 | $1.4M | $680,000 | +97.56% |
| Q3 2021 | 2021-09-30 | $460,000 | $322,000 | +233.33% |
| Q2 2021 | 2021-06-30 | $1.7M | $1.1M | +199.82% |
| Q1 2021 | 2021-03-31 | $458,000 | −$68,000 | −12.93% |
| Q4 2020 | 2020-12-31 | $697,000 | −$194,000 | −21.77% |
| Q3 2020 | 2020-09-30 | $138,000 | −$361,000 | −72.34% |
| Q2 2020 | 2020-06-30 | $564,000 | −$92,000 | −14.02% |
| Q1 2020 | 2020-03-31 | $526,000 | $227,000 | +75.92% |
| Q4 2019 | 2019-12-31 | $891,000 | $587,000 | +193.09% |
| Q3 2019 | 2019-09-30 | $499,000 | −$649,000 | −56.53% |
| Q2 2019 | 2019-06-30 | $656,000 | −$4.1M | −86.17% |
| Q1 2019 | 2019-03-31 | $299,000 | −$377,000 | −55.77% |
| Q4 2018 | 2018-12-31 | $304,000 | $131,000 | +75.72% |
| Q3 2018 | 2018-09-30 | $1.1M | $1.1M | +5118.18% |
| Q2 2018 | 2018-06-30 | $4.7M | $4.5M | +2271.00% |
| Q1 2018 | 2018-03-31 | $676,000 | $301,000 | +80.27% |
| Q4 2017 | 2017-12-31 | $173,000 | $173,000 | — |
| Q3 2017 | 2017-09-30 | $22,000 | $22,000 | — |
| Q2 2017 | 2017-06-30 | $200,000 | $200,000 | — |
| Q1 2017 | 2017-03-31 | $375,000 | $375,000 | — |
| Q4 2016 | 2016-12-31 | $0 | — | — |
| Q3 2016 | 2016-09-30 | $0 | — | — |
| Q2 2016 | 2016-06-30 | $0 | — | — |
| Q1 2016 | 2016-03-31 | $0 | — | — |
Mustang Bio capital expenditures (capex) trends
Over the last five fiscal years, Mustang Bio's capital expenditures (capex) decreased from $2.3M to $0, a change of −$2.3M. The latest reported quarter, Q3 2024, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mustang Bio source filings ↗